Altor BioScience Clinical Trials
Sponsors / Altor BioScience
ClinicalTrials.gov lists 16 trials for which Altor BioScience is named as lead sponsor. Of these, 0 are recruiting, 0 are active without new recruitment, and 11 have completed. The registry records 5 terminated or withdrawn trials for Altor BioScience. The most common reasons cited for termination include slow or insufficient recruitment. Planned participant enrollment across these trials sums to 530. Figures on this page are sourced from ClinicalTrials.gov and refreshed with each registry update.
16
Total Trials
0
Recruiting
0
Other Active
11
Completed
5
Terminated / Withdrawn
530
Total Enrollment
Termination reasons: Other60% · Recruitment40%
Recent Terminations
- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma"Change in drug product development strategy."
- NCT04142359 Stopped Apr 2020Pharmacokinetics"Study was closed due to the recent pandemic and enrollment challenges."
- Relapsed or Refractory Multiple Myeloma"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention"
- Non-muscle Invasive Bladder Cancer"The study was terminated early due to low enrollment."
- Relapsed or Refractory Multiple Myeloma"Patient population did not benefit from single agent treatment."
Top Conditions
Acute lung injury (2) Relapsed or refractory multiple myeloma (2) Advanced pancreatic cancer (1) Advanced solid tumors (1) Healthy (1) Locally advanced malignant neoplasm (1) Malignant tumor of renal pelvis (1) Metastatic melanoma (1) Non-muscle invasive bladder cancer (1) Non-small cell lung cancer (1)